Topic Archives: Steven Longenecker

Dave Lashmet has been a biotech/medical analyst and sometimes a newsletter editor at Stansberry for a long time, and the latest iteration of his high-end newsletter is now called Stansberry Venture Technology (currently “on sale” for $2,500, no refunds)… and it’s now being promoted with a “cure for cancer” spiel, so we obviously all want […]

Comments

  • paulamichelle

    Can anyone tell me the 3 top marijuana stocks Iain Butler of Motley Fool Canada is teasing ,I just received an offer for...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info